That the DSMB chose to continue the trial, NOT HALT it.
Blatantly false. The DSMB recommends halts for safety, efficacy and futility. They report to the sponsor for futility or efficacy and the FDA for safety. Then the FDA halts the trial for safety or the sponsor chooses to halt it for efficacy or futility.